You are here

Recent Pfizer Press Releases

6/7/16 7:00am EDT
Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ® (Tofacitinib Citrate) in Adults with Psoriatic Arthritis

Pfizer Inc. (NYSE:PFE) announced today top-line results from Oral Psoriatic Arthritis triaL (OPAL) Beyond, the second Phase 3 study of XELJANZ® (tofacitinib citrate) being investigated in patients with active psoriatic arthritis (PsA).

more...
6/6/16 9:00am EDT
ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma

•First pivotal study for Merck KGaA, Darmstadt, Germany, and Pfizer’s investigational anti-PD-L1 antibody avelumab shows clinically meaningful tumor responses in pre-treated metastatic Merkel cell carcinoma (MCC)
•International, multicenter Phase II study results in metastatic MCC with 88 patients represents largest data set of any anti-PD-L1/PD-1 reported in this patient population
•Plan to submit to regulatory authorities based on these results
 

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced results from the first pivotal, international, multicenter, open-label, Phase II study of avelumab*, which showed a 31.8% objective response rate (ORR) (28 of 88 patients; 95.9% CI: 21.9–43.1%), in the pre-planned primary analysis of the study, and a manageable safety profile in patients with metastatic Merkel cell carcinoma (MCC) who were treated with avelumab in second or subsequent lines of therapy.

more...
6/6/16 8:00am EDT
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer

Study Results Presented as Oral Abstract at ASCO 2016

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. These data were presented today in an oral presentation at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

more...
6/4/16 8:00am EDT
Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations

Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1 inhibitor, in patients with advanced solid tumors. This is the first reported study of a 4-1BB agonist combined with a checkpoint inhibitor. Encouraging safety data from the study were shared today as an oral presentation at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

more...
5/26/16 10:38am EDT
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the Bernstein 32nd Annual Strategic Decisions Conference on Thursday, June 2, 2016 at 2:00 p.m. Eastern Daylight Time.

more...
5/23/16 7:00am EDT
CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP

Black triangle indicating additional safety monitoring requirement for CHAMPIX in the EU has been removed

 

 

more...
5/20/16 8:00am EDT
Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA® (Meningococcal Group B Vaccine)

Pfizer Inc. (NYSE:PFE) today announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA® (Meningococcal Group B Vaccine) for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older. The acceptance marks the beginning of the regulatory review process for this vaccine in the EU.

more...
5/19/16 6:30am EDT
Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression

  • Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression
  • Therapeutic Factor IX activity sustained at levels exceeding those considered sufficient to reduce the risk of joint bleeds and need for prophylactic clotting Factor infusions
  • Expanded dataset on first cohort to be presented June 11 at European Hematology Association meeting

5/18/16 5:30pm EDT
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

  • 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer
  • Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma
  • Data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers
  • JAVELIN clinical program rapidly accelerating

ASCO Abstract #
8503, 9508, 4009, 4514, 4516, 9036, TPS4134, TPS4135, TPS9105, 3055, TPS3106, 5533, TPS5600, TPS4580

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that avelumab* presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3–7, 2016, in Chicago, IL.

more...
5/18/16 5:00pm EDT
Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

More than 40 accepted abstracts highlight innovation in immuno-oncology and other novel modalities across multiple tumor types

Pfizer invites public to view and listen to webcast of conference call with analysts on Wednesday, June 8 at 10 a.m. EDT to review oncology business and ASCO data presentations

 

Pfizer Inc. (NYSE:PFE) today announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action. Presentations include eight oral presentations and five poster discussions that span Pfizer’s internal and collaborative scientific advances.

more...
5/17/16 8:00am EDT
Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)

Findings Show the Importance of Patient and Physician Dialogue to Achieve Optimal Disease Management Outcomes

Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management.

more...
5/16/16 6:45am EDT
Pfizer to Acquire Anacor

  • Strong fit with Pfizer’s Inflammation and Immunology portfolio
  • Expected to enhance near-term revenue growth for the innovative business
  • Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if approved, has the potential to be an important first-line treatment option for patients with atopic dermatitis

Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes.

more...
5/13/16 6:30am EDT
Pfizer Presents Results from Two Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting

Secondary Data Support That TRUMENBA® Protects Against Additional Meningococcal Serogroup B Strains

Pfizer Inc. (NYSE:PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responses against ten additional MnB strains, in both adolescents and young adults.

more...
5/11/16 8:00am EDT
Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

  • Metastatic Research Accounts for Only About 7 Percent of Total Breast Cancer Research Investment1
  • Awards Complement Ongoing Initiative, Which has Reached More Than 40 Million People to Date

Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering gaps in the public’s knowledge of MBC and bringing greater attention to the unique needs and experiences of people living with this disease.

more...
5/3/16 6:45am EDT
PFIZER REPORTS FIRST-QUARTER 2016 RESULTS

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
more...
4/28/16 12:00pm EDT
Pfizer Hosts Annual Meeting of Shareholders

Declares 30-Cent Second-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent second-quarter 2016 dividend on the company’s common stock, payable June 1, 2016, to shareholders of record at the close of business on May 13, 2016.

more...
4/26/16 8:30am EDT
Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

Pfizer research program only one to assess role of PCSK9 inhibitors in reducing risk of cardiovascular events in high-risk patients without history of cardiovascular events

Pfizer Inc. today announced patient enrollment completion in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab.

more...
4/22/16 6:30pm EDT
CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

Authors conclude no significant increase in serious neuropsychiatric adverse events with CHANTIX/CHAMPIX relative to placebo or nicotine patch

Smokers treated with CHANTIX/CHAMPIX had significantly higher quit rates than those treated with bupropion, nicotine patch or placebo

Pfizer Inc. (NYSE:PFE) today announced results published in The Lancet from the largest clinical trial of approved smoking cessation medicines, called EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study).

more...
4/21/16 2:00pm EDT
Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 28, 2016.

more...

Pages